Edmund Dunn sold $9,174 of GLUE
Principal Accounting Officer at Monte Rosa Therapeutics, Inc.. 2,062 shares at an average of $4.45, traded Jun 3, 2025, filed Jun 4, 2025.
Score components
- +15RoleOfficer
- 0Trade size$9k at market
- 0Share of holdings soldSold 8.0% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-081637, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 3, 2025 | SOpen-market sale Common Stock | -2,062 | $4.45 | $9,174 | 23,732 | Jun 4, 2025 |
Related signals
Other insiders at Monte Rosa Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | GLUEsell Monte Rosa Therapeutics, Inc. | Matthew Bowen Principal Accounting Officer | $137 13 shares | -0% | |
| 37Weak | GLUEsell Monte Rosa Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $1.5M 157,895 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.